Martin Gartland

1.9k citations

19 papers · 866 indexed · 1 hit paper · h-index 11

Co-authors: Michael Aboud Brian Wynne Mark Underwood Lesley Kahl Kati Vandermeulen Kimberly Y. Smith Elizabeth A. Blair Chien‐Ching Hung
Topics: HIV/AIDS drug development and treatment (17 papers)HIV Research and Treatment (14 papers)HIV/AIDS Research and Interventions (8 papers)
Cited by: Virology Infectious Diseases Emergency Medicine
Journals: The Lancet Nucleic Acids Research Clinical Infectious Diseases
Partner nations: United Kingdom Spain United States

In The Last Decade

Martin Gartland

18 papers receiving 843 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

2018 243 citations Josep M. Llibre, Chien‐Ching Hung et al. The Lancet profile →

Peers

Countries citing papers authored by Martin Gartland

Since Specialization

Citations

This map shows the geographic impact of Martin Gartland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Gartland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Gartland more than expected).

Fields of papers citing papers by Martin Gartland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Gartland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Gartland. The network helps show where Martin Gartland may publish in the future.

Co-authorship network of co-authors of Martin Gartland

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Gartland. A scholar is included among the top collaborators of Martin Gartland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Gartland. Martin Gartland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Phase 1 Evaluation of VH4524184, a Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile 2025 ·Clinical Infectious Diseases ·(unknown),Mark Underwood,(unknown),José Castillo‐Mancilla,Lesley Kahl,(unknown),Gabriela Ghita,Jerry Jeffrey,Stephen Byrne,(unknown),Joseph Horton,Martin Gartland	0
2	A phase I, first‐in‐human study investigating the safety, tolerability, and pharmacokinetics of the maturation inhibitor GSK3739937 2023 ·Pharmacology Research & Perspectives ·Paul Benn,Ying Zhang,Lesley Kahl,Thomas Greene,(unknown),Cindy Fishman,(unknown),Martin Gartland	7
3	Open‐label, drug–drug interaction study between the HIV‐1 maturation inhibitor GSK3640254 and a metabolic probe cocktail in healthy participants 2023 ·British Journal of Clinical Pharmacology ·Ying Zhang,Mark Johnson,Samit R. Joshi,(unknown),(unknown),(unknown),(unknown),Martin Gartland,Max Lataillade	1
4	Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254 2022 ·Clinical Infectious Diseases ·Christoph D. Spinner,Franco Felizarta,Giuliano Rizzardini,Patrick Philibert,Essack Mitha,Peré Domingo,Christoph Stephan,(unknown),(unknown),(unknown),Teodora Pene Dumitrescu,Jerry Jeffrey,(unknown),(unknown),(unknown),Mark R. Johnson,Martin Gartland,Samit R. Joshi,Max Lataillade	15
5	Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study 2020 ·Clinical Infectious Diseases ·Jean van Wyk,Faïza Ajana,Fiona Bisshop,Stéphane De Wit,Olayemi Osiyemi,Joaquín Portilla,Jean‐Pierre Routy,Christoph Wyen,Mounir Ait‐Khaled,Maria Cláudia Nascimento,Keith A. Pappa,Ruolan Wang,Jonathan Wright,Allan R. Tenorio,Brian Wynne,Michael Aboud,Martin Gartland,Kimberly Y. Smith	171
6	Switching to DTG/3TC fixed-dose combination (FDC) Is non-inferior to continuing a TAF-based regimen in maintaining virologic suppression through 48 weeks (TANGO Study) 2020 ·Journal of Infection and Public Health ·Jean van Wyk,F. Ajana,Fiona Bisshop,(unknown),(unknown),Joaquín Portilla,Jean‐Pierre Routy,Christoph Wyen,Mounir Ait‐Khaled,(unknown),Keith A. Pappa,(unknown),(unknown),(unknown),Brian Wynne,Michael Aboud,Martin Gartland,Kate Smith,(unknown)	6
7	Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis 2020 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Joseph J. Eron,Chien‐Ching Hung,Jean‐Guy Baril,Jihad Slim,Vicenç Falcó,Johannes R. Bogner,Franco Maggiolo,Anthony Mills,Jörg Sievers,Choy Man,(unknown),Mark Underwood,Allan R. Tenorio,Keith A. Pappa,Brian Wynne,Justin Koteff,Martin Gartland,Kimberly Y. Smith,Michael Aboud	15
8	Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials 2020 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Jean van Wyk,Chloe Orkin,Rafael Rubio,Johannes R. Bogner,David Baker,Marie-Aude Khuong-Josses,(unknown),Konstantinos Angelis,Lesley Kahl,Jessica Matthews,Ruolan Wang,Mark Underwood,Brian Wynne,(unknown),Kati Vandermeulen,Martin Gartland,Kimberly Y. Smith	32
9	Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies 2019 ·The Lancet HIV ·Michael Aboud,Chloe Orkin,Daniel Podzamczer,Johannes R. Bogner,David Baker,Marie-Aude Khuong-Josses,(unknown),Konstantinos Angelis,Lesley Kahl,Elizabeth A. Blair,Kimberly K. Adkison,Mark Underwood,Jessica Matthews,Brian Wynne,Kati Vandermeulen,Martin Gartland,Kimberly Y. Smith	77
10	Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial 2019 ·The Lancet Infectious Diseases ·Michael Aboud,Richard Kaplan,Johannes Lombaard,Fujie Zhang,José A. Hidalgo,(unknown),Marcelo Losso,Ploenchan Chetchotisakd,Carlos Brites,Jörg Sievers,Dannae Brown,(unknown),Mark Underwood,Maria Cláudia Nascimento,Yogesh Punekar,Martin Gartland,Kimberly Y. Smith	104
11	Superior Efficacy of Dolutegravir (DTG) Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Compared with lopinavir/ritonavir (LPV/r) Plus 2 NRTIs in Second-Line Treatment — 48-week Data from the DAWNING Study 2019 ·Journal of Infection and Public Health ·Michael Aboud,Richard Kaplan,Johannes Lombaard,(unknown),José A. Hidalgo,(unknown),Marcelo Losso,Ploenchan Chetchotisakd,Carlos Brites,Jörg Sievers,Dannae Brown,(unknown),Mark Underwood,(unknown),Martin Gartland,(unknown),(unknown),José M. Gatell	5
12	Initial viral load decline and response rates by baseline viral load strata with dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled results from the GEMINI studies 2019 ·Journal of Infection and Public Health ·Joseph J. Eron,Chien‐Ching Hung,Jean‐Guy Baril,Jihad Slim,Vicenç Falcó,Johannes R. Bogner,Franco Maggiolo,Anthony Mills,Jörg Sievers,Choy Man,Alexander Currie,Mark Underwood,Allan R. Tenorio,Keith A. Pappa,Brian Wynne,Justin Koteff,Martin Gartland,Kimberly Y. Smith,Michael Aboud,(unknown)	3
13	2484. Patient Reported Outcomes After Switching to a 2-Drug Regimen of Dolutegravir + Rilpivirine: Week 148 Results from the Sword-1 and Sword-2 Studies 2019 ·Open Forum Infectious Diseases ·Alan Oglesby,(unknown),Yogesh Punekar,Vasiliki Chounta,Antonio Antela,Jessica Matthews,Lesley Kahl,Martin Gartland,Brian Wynne,Miranda Murray,(unknown)	2
14	Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studiesbreakdown → 2018 ·The Lancet ·Josep M. Llibre,Chien‐Ching Hung,Cynthia Brinson,Francesco Castelli,Pierre‐Marie Girard,Lesley Kahl,Elizabeth A. Blair,(unknown),Brian Wynne,Kati Vandermeulen,Mark Underwood,(unknown),Martin Gartland,Michael Aboud	243
15	Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health 2017 ·AIDS ·Grace A. McComsey,Sergio Lupo,(unknown),(unknown),(unknown),Lesley Kahl,(unknown),Brian Wynne,Kati Vandermeulen,Martin Gartland,(unknown),Michael Aboud	43
16	96-Week Results of Abacavir/Lamivudine versus Tenofovir/Emtricitabine, plus Efavirenz, in Antiretroviral-Naive, HIV-1-Infected Adults: Assert Study 2013 ·Antiviral Therapy ·Graeme Moyle,Hans‐Jürgen Stellbrink,Juliet Compston,Chloe Orkin,José Ramón Arribas,Peré Domingo,Catherine Granier,Helen Pearce,(unknown),Martin Gartland,(unknown)	52
17	Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies 2000 ·AIDS ·Michael Maguire,Martin Gartland,Sarah Moore,Andrew Hill,Margaret Tisdale,Richard Harrigan,Jőrg‐Peter Kleim	63
18	Avanti 1: Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Zidovudine plus Lamivudine versus Zidovudine plus Lamivudine plus Loviride in HIV-Infected Antiretroviral-Naive Patients 1999 ·Antiviral Therapy ·Josep M. Gatell,J Lange,Martin Gartland,(unknown)	17
19	Vectors with multiple insertion sites for expression of cloned genes by T7 RNA polymerase: expression of a peptide from EBV thymidine kinase (TK) 1990 ·Nucleic Acids Research ·M. Mackett,E. Littler,(unknown),Martin Gartland,J. R. Arrand	10

About Martin Gartland

Martin Gartland is a scholar working on Virology, Infectious Diseases and Emergency Medicine, having authored 19 papers that have together received 866 indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (17 papers), HIV Research and Treatment (14 papers) and HIV/AIDS Research and Interventions (8 papers). The work is most often cited by research in Virology (634 citations), Infectious Diseases (794 citations) and Emergency Medicine (262 citations). Martin Gartland has collaborated with scholars based in United Kingdom, Spain and United States. Frequent co-authors include Michael Aboud, Brian Wynne, Mark Underwood, Lesley Kahl, Kati Vandermeulen, Kimberly Y. Smith, Elizabeth A. Blair, Chien‐Ching Hung, Cynthia Brinson and Josep M. Llibre. Their work appears in journals such as The Lancet, Nucleic Acids Research and Clinical Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact